<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258049</url>
  </required_header>
  <id_info>
    <org_study_id>ART004</org_study_id>
    <nct_id>NCT01258049</nct_id>
  </id_info>
  <brief_title>Superiority of ArTiMist Versus Quinine in Children With Severe Malaria</brief_title>
  <official_title>A Phase III, Randomised, Open Labelled, Active Controlled, Multi Centre, Superiority Trial of ArTiMist™ Versus Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proto Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proto Pharma Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that ArTiMist (sublingual artemether spray) is
      better than intravenous quinine in reducing parasite counts by &gt;= 90% within 24 hours after
      the start of treatment in children with severe malaria, or uncomplicated malaria with
      gastrointestinal complications
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malaria causes significant morbidity and mortality in children in developing countries,
      despite the availability of highly effective antimalarial therapy. One of the key
      contributing factors is the delay in the initiation of treatment.

      ArTiMist is a sublingual formulation of the established antimalarial treatment, artemether.
      In previous studies good bioavailability has been demonstrated. In an exploratory study
      (ART003) ArTiMist demonstrated a non statistically significant improvement of 26% (when
      compared to intravenous quinine) in the numbers of patients experiencing a parasite reduction
      of &gt;= 90% within 24 hours of the initiation of treatment.

      This Phase 3 study is being conducted to establish whether treatment with ArTiMist in
      children with severe falciparum malaria or uncomplicated falciparum malaria with
      gastrointestinal complications is at least 20% superior in providing parasitological success
      (defined as &gt;= 90% reduction in parasite count at 24 hours after start of treatment) when
      compared to intravenous quinine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parasitological Success (MITT)</measure>
    <time_frame>24 hours after start of treatment</time_frame>
    <description>Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parasitological Success (PP)</measure>
    <time_frame>24 hours after start of treatment</time_frame>
    <description>Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time (PCT) [MITT Population]</measure>
    <time_frame>28 days after start of treatment</time_frame>
    <description>Parasite clearance time (PCT). Time in hours from the initiation of therapy until the first of two successive parasite negative smears (zero parasite counts) are obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCT 90 [MITT Population]</measure>
    <time_frame>28 days after start of treatment</time_frame>
    <description>Time for parasite counts to fall by 90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCT 50 [MITT Population]</measure>
    <time_frame>28 days after start of treatment</time_frame>
    <description>Time for parasite counts to fall by 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRR 24 [MITT Population]</measure>
    <time_frame>28 days after start of treatment</time_frame>
    <description>The percentage reduction in parasite counts 24 hours after first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRR 12 [MITT Population]</measure>
    <time_frame>28 days after start of treatment</time_frame>
    <description>The percentage reduction in parasite counts 12 hours after first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance Time (FCT)</measure>
    <time_frame>28 days after start of treatment</time_frame>
    <description>Time in hours from the initiation of therapy until the disappearance of fever (tympanic temperature &lt; 38.0) that lasted at least 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Cure Rate</measure>
    <time_frame>28 days after the start of treatment</time_frame>
    <description>The complete resolution of clinical signs and symptoms, malaria-related laboratory abnormalities, and elimination of asexual parasites by Day 7, with no recurrence up to Day 28 (+/- 2 days), and the 48h parasite count to be &lt; 25% of baseline with no clinical deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Treatment Failure</measure>
    <time_frame>Three days after the start of treatment</time_frame>
    <description>Early treatment failure is indicated by one or more of the following:
Parasite count on Day 2 &gt; Day 0, irrespective of temperature
Parasite count on Day 3 &gt; 0 with tympanic temperature ≥ 38.0°C
Parasite count on Day 3 ≥ 25% of baseline
Administration of rescue antimalarial treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Clinical Failure</measure>
    <time_frame>28 days after the start of treatment</time_frame>
    <description>Signs of severe malaria on any day between Day 4 and Day 28 in the presence of parasitaemia, without previously meeting any of the criteria of early treatment failure
Presence of parasitaemia and tympanic temperature ≥ 38.0°C (or history of fever), on any day between Day 4 and Day 28, without previously meeting any of the criteria of early treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Parasitological Failure</measure>
    <time_frame>28 days after the start of treatment</time_frame>
    <description>o Parasitaemia on any day from Day 7 to Day 28 and tympanic temperature ≤ 38.0°C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Full Consciousness</measure>
    <time_frame>28 days after start of treatment</time_frame>
    <description>Time in hours to return to full consciousness (Blantyre Coma Scale = 5), if level of consciousness is reduced (Blantyre Coma Scale &lt;5) prior to dosing or within 24hours of first dosing.
For the Blantyre Coma Scale
Total - maximum 5, eye movement - maximum 1, best motor response - maximum 2, best verbal response - maximum 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Normal Per os Status</measure>
    <time_frame>28 days after start of treatment</time_frame>
    <description>Time in hours to return to normal per os status. Normal per os was when the investigator considered the patient to be able to eat and drink normally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities</measure>
    <time_frame>28 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths or Neurological Sequelae at Day 28</measure>
    <time_frame>28 days after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>ArTiMist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Quinine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether Sublingual Spray</intervention_name>
    <description>Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints</description>
    <arm_group_label>ArTiMist</arm_group_label>
    <other_name>ArTiMist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinine</intervention_name>
    <description>Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours</description>
    <arm_group_label>Quinine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient's legally acceptable representative has provided informed consent and the
             patient has assented (where relevant) to participation in the trial

          2. The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive

          3. The patient has falciparum malaria as evidenced by thick or thin blood smears of ≥ 500
             P Falciparum per mcl (patients with mixed infections may be included provided ≥ 500 P
             Falciparum per mcl)

          4. The patient has either:

               -  severe or complicated falciparum malaria as determined by the investigator based
                  on the WHO criteria for severity, and/or

               -  uncomplicated falciparum malaria but is unable to tolerate oral medication as a
                  result of gastrointestinal complications such as vomiting or diarrhoea.

        Exclusion Criteria:

          1. The patient's legally acceptable representative does not provide informed consent for
             participation, or the child if capable, does not assent to participation in the trial.

          2. Ability to tolerate oral therapy

          3. Patient has received any antimalarial therapy within the 7 days prior to first study
             drug administration.

          4. Patient has evidence of significant co-infections (this does not include mixed
             Plasmodium infections).

          5. Patient has a contraindication, allergy or is otherwise intolerant to either
             artemether or quinine .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryl Bendel, MBChB MFPM</last_name>
    <role>Study Chair</role>
    <affiliation>Xidea Solutions Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre National de Recherche et de Formation sur le Paludisme (CNRFP)</name>
      <address>
        <city>Ouagadougou</city>
        <zip>01 BP 2208</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Navrongo Health Research Centre</name>
      <address>
        <city>Navrongo</city>
        <zip>P.O. Box 114</zip>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rwinkwavu District Hospital</name>
      <address>
        <city>Rwinkwavu</city>
        <state>Eastern Province</state>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Ghana</country>
    <country>Rwanda</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2010</study_first_submitted>
  <study_first_submitted_qc>December 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2010</study_first_posted>
  <results_first_submitted>September 13, 2013</results_first_submitted>
  <results_first_submitted_qc>January 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2014</results_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmodium infections</keyword>
  <keyword>Remittent fever</keyword>
  <keyword>Artemether</keyword>
  <keyword>Artemesinins</keyword>
  <keyword>Quinine</keyword>
  <keyword>Malaria</keyword>
  <keyword>Protozoan infections</keyword>
  <keyword>sublingual drug delivery</keyword>
  <keyword>Parasitic disease</keyword>
  <keyword>Antiprotozoan agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Quinine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ArTiMist</title>
          <description>Doses of 3 mg/kg were administered sublingually at: 0 h, 8 h, 24 h, 36 h, 48 h, and 60 h. Following the initial six doses, subjects could, at the discretion of the Investigator receive a further four daily doses of 3 mg/kg ArTiMist™ to complete a seven day treatment course, or be converted to another suitable treatment or a suitable course of combination therapy in accordance with national drugs policy where applicable.</description>
        </group>
        <group group_id="P2">
          <title>Quinine</title>
          <description>A loading dose of 20 mg/kg was given over four hours and thereafter 10 mg/kg was given every eight hours until the subject was able to swallow. Thereafter, patients were given quinine syrup or crushed tablets (10 mg/kg every eight hours) or another suitable treatment to ensure they received at least seven days of therapy, or be converted to another suitable treatment or a suitable course of combination therapy, in accordance with national drugs policy where applicable.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ArTiMist</title>
          <description>Doses of 3 mg/kg were administered sublingually at: 0 h, 8 h, 24 h, 36 h, 48 h, and 60 h.
Following the initial six doses, subjects could, at the discretion of the Investigator receive a further four daily doses of 3 mg/kg ArTiMist™ to complete a seven day treatment course, or be converted to another suitable treatment or a suitable course of combination therapy in accordance with national drugs policy where applicable.</description>
        </group>
        <group group_id="B2">
          <title>Quinine</title>
          <description>A loading dose of 20 mg/kg was given over four hours and thereafter 10 mg/kg was given every eight hours until the subject was able to swallow. Thereafter, patients were given quinine syrup or crushed tablets (10 mg/kg every eight hours) or another suitable treatment to ensure they received at least seven days of therapy, or be converted to another suitable treatment or a suitable course of combination therapy, in accordance with national drugs policy where applicable</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="1.34"/>
                    <measurement group_id="B2" value="2.5" spread="1.23"/>
                    <measurement group_id="B3" value="2.6" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ghana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burkina Faso</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rwanda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Definition - Severe or complicated malaria</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Severe or complicated malaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncomplicated malaria with GI complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.7" spread="2.4"/>
                    <measurement group_id="B2" value="11.2" spread="2.5"/>
                    <measurement group_id="B3" value="11.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulse rate</title>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146" spread="20.2"/>
                    <measurement group_id="B2" value="147" spread="26.3"/>
                    <measurement group_id="B3" value="146" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tympanic Temperature</title>
          <units>Degrees Centigrade</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="1.1"/>
                    <measurement group_id="B2" value="38.6" spread="1.0"/>
                    <measurement group_id="B3" value="38.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Respiratory Rate</title>
          <units>breaths/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="11.0"/>
                    <measurement group_id="B2" value="35.9" spread="11.3"/>
                    <measurement group_id="B3" value="36.3" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blantyre Coma Scale</title>
          <description>Blantyre Coma scale scores out of 5, full consciousness, by adding the scores of the following 3 domains. Any score ≤ 4 is considered abnormal,
Eye Movement
1 Watches or follows 0 Fails to watch or follow
Best Motor Response 2 Localizes painful stimulus 1 Withdraws limb from painful stimulus 0 No response or inappropriate response
Best Verbal Response 2 Cries appropriately with pain, or if verbal, speaks
1 Moan or abnormal cry with pain 0 No vocal response with pain</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parasite Counts</title>
          <units>p falciparum /mcl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133884" spread="129715"/>
                    <measurement group_id="B2" value="155321" spread="202213"/>
                    <measurement group_id="B3" value="144602" spread="165964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parasite Count (median)</title>
          <units>p falciparum /mcl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86572" lower_limit="279" upper_limit="515556"/>
                    <measurement group_id="B2" value="66077" lower_limit="1225" upper_limit="843746"/>
                    <measurement group_id="B3" value="76325" lower_limit="279" upper_limit="843746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Parasitological Success (MITT)</title>
        <description>Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose</description>
        <time_frame>24 hours after start of treatment</time_frame>
        <population>The Modified Intention to Treat (MITT) population included all randomised subjects who received at least one dose of study medication and had evaluable parasite counts at 24 hours after first dosing.
7 subjects for ArTiMist and 3 subjects for quinine were excluded due to no baseline or 24 h parasite count</population>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Parasitological Success (MITT)</title>
          <description>Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose</description>
          <population>The Modified Intention to Treat (MITT) population included all randomised subjects who received at least one dose of study medication and had evaluable parasite counts at 24 hours after first dosing.
7 subjects for ArTiMist and 3 subjects for quinine were excluded due to no baseline or 24 h parasite count</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>In ART003, the parasite success rate for quinine was 67.7%. On the assumption that the parasite success rate was 70% for quinine in this study and in order to demonstrate that ArTiMist™ is superior to quinine by at least 20% the success rate for ArTiMist™ should be at least 90%. Using these figures, and assuming a power of 80%, an alpha of 0.05 (two sided) and based on an equal allocation to the ArTiMist™ and quinine treatment arms, the number of subjects (n) required on each treatment was 59.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>Regression, Logistic</method>
            <param_type>Percentage Difference</param_type>
            <param_value>54.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.25</ci_lower_limit>
            <ci_upper_limit>67.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance Time (PCT) [MITT Population]</title>
        <description>Parasite clearance time (PCT). Time in hours from the initiation of therapy until the first of two successive parasite negative smears (zero parasite counts) are obtained</description>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance Time (PCT) [MITT Population]</title>
          <description>Parasite clearance time (PCT). Time in hours from the initiation of therapy until the first of two successive parasite negative smears (zero parasite counts) are obtained</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.29" spread="13.21"/>
                    <measurement group_id="O2" value="68.30" spread="98.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-38.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.22</ci_lower_limit>
            <ci_upper_limit>-15.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCT 90 [MITT Population]</title>
        <description>Time for parasite counts to fall by 90%</description>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>PCT 90 [MITT Population]</title>
          <description>Time for parasite counts to fall by 90%</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.02" spread="5.82"/>
                    <measurement group_id="O2" value="27.93" spread="18.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.38</ci_lower_limit>
            <ci_upper_limit>-8.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCT 50 [MITT Population]</title>
        <description>Time for parasite counts to fall by 50%</description>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>PCT 50 [MITT Population]</title>
          <description>Time for parasite counts to fall by 50%</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="5.72"/>
                    <measurement group_id="O2" value="18.58" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>Regression, Cox</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.71</ci_lower_limit>
            <ci_upper_limit>- 6.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRR 24 [MITT Population]</title>
        <description>The percentage reduction in parasite counts 24 hours after first dose</description>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>PRR 24 [MITT Population]</title>
          <description>The percentage reduction in parasite counts 24 hours after first dose</description>
          <units>percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" spread="6.12"/>
                    <measurement group_id="O2" value="44.5" spread="114.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>54.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.05</ci_lower_limit>
            <ci_upper_limit>80.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRR 12 [MITT Population]</title>
        <description>The percentage reduction in parasite counts 12 hours after first dose</description>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>PRR 12 [MITT Population]</title>
          <description>The percentage reduction in parasite counts 12 hours after first dose</description>
          <units>percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="70.28"/>
                    <measurement group_id="O2" value="-132.2" spread="765.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>174.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.44</ci_lower_limit>
            <ci_upper_limit>358.61</ci_upper_limit>
            <estimate_desc>mean parasite counts increased in the first 12 hours for patients on quinine treatment</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Clearance Time (FCT)</title>
        <description>Time in hours from the initiation of therapy until the disappearance of fever (tympanic temperature &lt; 38.0) that lasted at least 24 hours.</description>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Fever Clearance Time (FCT)</title>
          <description>Time in hours from the initiation of therapy until the disappearance of fever (tympanic temperature &lt; 38.0) that lasted at least 24 hours.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" spread="34.47"/>
                    <measurement group_id="O2" value="41.6" spread="22.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Regression, Cox</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.16</ci_lower_limit>
            <ci_upper_limit>12.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Cure Rate</title>
        <description>The complete resolution of clinical signs and symptoms, malaria-related laboratory abnormalities, and elimination of asexual parasites by Day 7, with no recurrence up to Day 28 (+/- 2 days), and the 48h parasite count to be &lt; 25% of baseline with no clinical deterioration</description>
        <time_frame>28 days after the start of treatment</time_frame>
        <population>For some subjects, this endpoint was not evaluable and/or not all data was received.</population>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Complete Cure Rate</title>
          <description>The complete resolution of clinical signs and symptoms, malaria-related laboratory abnormalities, and elimination of asexual parasites by Day 7, with no recurrence up to Day 28 (+/- 2 days), and the 48h parasite count to be &lt; 25% of baseline with no clinical deterioration</description>
          <population>For some subjects, this endpoint was not evaluable and/or not all data was received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Regression, Logistic</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Treatment Failure</title>
        <description>Early treatment failure is indicated by one or more of the following:
Parasite count on Day 2 &gt; Day 0, irrespective of temperature
Parasite count on Day 3 &gt; 0 with tympanic temperature ≥ 38.0°C
Parasite count on Day 3 ≥ 25% of baseline
Administration of rescue antimalarial treatment</description>
        <time_frame>Three days after the start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Early Treatment Failure</title>
          <description>Early treatment failure is indicated by one or more of the following:
Parasite count on Day 2 &gt; Day 0, irrespective of temperature
Parasite count on Day 3 &gt; 0 with tympanic temperature ≥ 38.0°C
Parasite count on Day 3 ≥ 25% of baseline
Administration of rescue antimalarial treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Clinical Failure</title>
        <description>Signs of severe malaria on any day between Day 4 and Day 28 in the presence of parasitaemia, without previously meeting any of the criteria of early treatment failure
Presence of parasitaemia and tympanic temperature ≥ 38.0°C (or history of fever), on any day between Day 4 and Day 28, without previously meeting any of the criteria of early treatment failure</description>
        <time_frame>28 days after the start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Late Clinical Failure</title>
          <description>Signs of severe malaria on any day between Day 4 and Day 28 in the presence of parasitaemia, without previously meeting any of the criteria of early treatment failure
Presence of parasitaemia and tympanic temperature ≥ 38.0°C (or history of fever), on any day between Day 4 and Day 28, without previously meeting any of the criteria of early treatment failure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parasitological Success (PP)</title>
        <description>Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose</description>
        <time_frame>24 hours after start of treatment</time_frame>
        <population>The Per Protocol (PP) population included the subjects in the MITT population who had received at least 80% of doses up to the time of discharge from the hospital, had evaluable data up to and including Day 28 and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Parasitological Success (PP)</title>
          <description>Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose</description>
          <population>The Per Protocol (PP) population included the subjects in the MITT population who had received at least 80% of doses up to the time of discharge from the hospital, had evaluable data up to and including Day 28 and had no major protocol violations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.005</p_value>
            <method>Regression, Linear</method>
            <param_type>Percentage Difference</param_type>
            <param_value>55.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.44</ci_lower_limit>
            <ci_upper_limit>67.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Parasitological Failure</title>
        <description>o Parasitaemia on any day from Day 7 to Day 28 and tympanic temperature ≤ 38.0°C</description>
        <time_frame>28 days after the start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Late Parasitological Failure</title>
          <description>o Parasitaemia on any day from Day 7 to Day 28 and tympanic temperature ≤ 38.0°C</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Full Consciousness</title>
        <description>Time in hours to return to full consciousness (Blantyre Coma Scale = 5), if level of consciousness is reduced (Blantyre Coma Scale &lt;5) prior to dosing or within 24hours of first dosing.
For the Blantyre Coma Scale
Total - maximum 5, eye movement - maximum 1, best motor response - maximum 2, best verbal response - maximum 2</description>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Full Consciousness</title>
          <description>Time in hours to return to full consciousness (Blantyre Coma Scale = 5), if level of consciousness is reduced (Blantyre Coma Scale &lt;5) prior to dosing or within 24hours of first dosing.
For the Blantyre Coma Scale
Total - maximum 5, eye movement - maximum 1, best motor response - maximum 2, best verbal response - maximum 2</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="9.58"/>
                    <measurement group_id="O2" value="23.0" spread="16.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Normal Per os Status</title>
        <description>Time in hours to return to normal per os status. Normal per os was when the investigator considered the patient to be able to eat and drink normally.</description>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Normal Per os Status</title>
          <description>Time in hours to return to normal per os status. Normal per os was when the investigator considered the patient to be able to eat and drink normally.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="12.89"/>
                    <measurement group_id="O2" value="25.3" spread="16.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities</title>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths or Neurological Sequelae at Day 28</title>
        <time_frame>28 days after start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ArTiMist</title>
          </group>
          <group group_id="O2">
            <title>Quinine</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths or Neurological Sequelae at Day 28</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the time of signing informed consent until the final study visit. Adverse events that started or worsened after start of treatment were considered Treatment Emergent.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ArTiMist</title>
        </group>
        <group group_id="E2">
          <title>Quinine</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Cerebral Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="77"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Daryl Bendel</name_or_title>
      <organization>Xidea Solutions Limited</organization>
      <email>daryl@xideasolutions.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

